Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина 2020;23(3):149–55. DOI: 10.17116/profmed202023031149.
DOI: 10.17116/profmed202023031149

Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2022;12(3s2):607–26. DOI: 10.18027/2224-5057-2022-12-3s2-607-626.
DOI: 10.18027/2224-5057-2022-12-3s2-607-626

Kim M., Hwang S., Ahn H. et al. Diagnostic yield of multiparametric MRI for local recurrence at biochemical recurrence after radical prostatectomy. Prostate Int 2022;10(3):135–41. DOI: 10.1016/j.prnil.2022.05.001.
DOI: 10.1016/j.prnil.2022.05.001

Петровский Н.В., Глыбочко П.В., Аляев Ю.Г. и др. Локальный рецидив рака предстательной железы после радикальной простатэктомии. Урология 2017;(4):85–90. DOI: 10.18565/urol.2017.4.85-90.
DOI: 10.18565/urol.2017.4.85-90

De Visschere P.J.L., Standaert C., Fütterer J.J. et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2019;2(1):47–76. DOI: 10.1016/j.euo.2018.09.010.
DOI: 10.1016/j.euo.2018.09.010

Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Рак предстательной железы. Клинические рекомендации. Современная онкология 2021;23(2):211–47. DOI: 10.26442/18151434.2021.2.200959.
DOI: 10.26442/18151434.2021.2.200959

Teeter A.E., Griffin K., Howard L.E. et al. Does early prostate specific antigen doubling time after radical prostatectomy, calculated prior to prostate specific antigen recurrence, correlate with prostate cancer outcomes? A report from the SEARCH Database Group. J Urol 2018;199(3):713–8. DOI: 10.1016/j.juro.2017.08.107.
DOI: 10.1016/j.juro.2017.08.107

Cornford P., van den Bergh R.C.N., Briers E. et al. EAU-EANMESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79(2):263–82. DOI: 10.1016/j.eururo.2020.09.046.
DOI: 10.1016/j.eururo.2020.09.046

Tokas T., Grabski B., Paul U. et al. A 12-year follow-up of ANNA/ C-TRUS image-targeted biopsies in patients suspicious for prostate cancer. World J Urol 2018;36(5):699–704. DOI: 10.1007/s00345-017-2160-z.
DOI: 10.1007/s00345-017-2160-z

Алексеев Б.Я., Нюшко К.М., Крашенинников А.А. и др. Методы диагностики и лечения олигометастазов у больных раком предстательной железы с прогрессированием заболевания после проведенного радикального лечения. Онкоурология 2016;12(2):64–73. DOI: 10.17650/1726-9776-2016-12-2-64-73.
DOI: 10.17650/1726-9776-2016-12-2-64-73

EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94 92671-19-6.

Chade D.C., Eastham J., Graefen M. et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61(5):961–71. DOI: 10.1016/j.eururo.2012.01.022.
DOI: 10.1016/j.eururo.2012.01.022

Magnetta M.J., Casalino D., Heller M.T. Imaging assessment of local recurrence of prostate cancer after radical prostatectomy. Abdom Radiol 2020;45(12):4073–83. DOI: 10.1007/s00261-020-02505-7.
DOI: 10.1007/s00261-020-02505-7

Panebianco V., Villeirs G., Weinreb J.C. et al. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol 2021;4(6):868–76. DOI: 10.1186/s13014-016-0671-1.
DOI: 10.1186/s13014-016-0671-1

Allen S.D., Thompson A., Sohaib S.A. The normal post-surgical anatomy of the male pelvis following radical prostatectomy as assessed by magnetic resonance imaging. Eur Radiol 2008;18(6):1281–91. DOI: 10.1007/s00330-008-0867-3.
DOI: 10.1007/s00330-008-0867-3

Mertan F.V., Greer M.D., Borofsky S. et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. Top Magn Reson Imaging 2016;25(3):139–47. DOI: 10.1097/RMR.0000000000000088.
DOI: 10.1097/RMR.0000000000000088

Patel P., Mathew M.S., Trilisky I., Oto A. Multiparametric MR imaging of the prostate after treatment of prostate cancer. Radiographics 2018;38(2):437–49. DOI: 10.1148/rg.2018170147.
DOI: 10.1148/rg.2018170147

Kowa J.Y., Soneji N., Sohaib S.A. et al. Detection and staging of radio-recurrent prostate cancer using multiparametric MRI. Br J Radiol 2021;94(1120):20201423. DOI: 10.1259/bjr.20201423.
DOI: 10.1259/bjr.20201423

Gaur S., Turkbey B. Prostate MR imaging for posttreatment evaluation and recurrence. Urol Clin North Am 2018;45(3):467–79. DOI: 10.1016/j.ucl.2018.03.011.
DOI: 10.1016/j.ucl.2018.03.011

Рубцова Н.А., Мищенко А.В., Данилов В.В. и др. PI-RADS v2.1: движение на пути к ясности (комментарии к обновленной версии). Онкоурология 2020;16(2):15–28. DOI: 10.17650/1726-9776-2020-16-2-15-28.
DOI: 10.17650/1726-9776-2020-16-2-15-28

Каприн А.Д., Бирюков В.А., Черниченко А.В. и др. Брахитерапия рака предстательной железы. Опыт работы филиалов Национального медицинского исследовательского центра радиологии. Онкоурология 2018;14(1):94–9. DOI: 10.17650/1726-9776-2018-14-1-94-99.
DOI: 10.17650/1726-9776-2018-14-1-94-99

Maurer T., Eiber M., Fanti S. et al. Imaging for prostate cancer recurrence. Eur Urol Focus 2016;2(2):139–50. DOI: 10.1016/j.euf.2016.02.006.
DOI: 10.1016/j.euf.2016.02.006

Van der Poel H., Grivas N., van Leeuwen P. et al. The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer. World J Urol 2019;37(8):1485–90. DOI: 10.1007/s00345-019-02677-y.
DOI: 10.1007/s00345-019-02677-y

Patel P., Oto A. Magnetic resonance imaging of the prostate, including pre- and postinterventions. Semin Intervent Radiol 2016;33(3):186–95. DOI: 10.1055/s-0036-1586144.
DOI: 10.1055/s-0036-1586144

Maenhout M., Van Vulpen M., Moerland M. et al. Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. J Contemp Brachytherapy 2017;9(2):161–6. DOI: 10.5114/jcb.2017.67015.
DOI: 10.5114/jcb.2017.67015

McCammack K.C., Raman S.S., Margolis D.J.A. Imaging of local recurrence in prostate cancer. Future Oncol 2016;12(21):2401–15. DOI: 10.2217/fon-2016-0122.
DOI: 10.2217/fon-2016-0122

Pucar D., Shukla-Dave A., Hricak H. et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005;236(2):545–53. DOI: 10.1148/radiol.2362040739.
DOI: 10.1148/radiol.2362040739

Dinis Fernandes C., van Houdt P.J., Heijmink S.W.T.P.J. et al. Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy. J Magn Reson Imaging 2019;50(1):269–78. DOI: 10.1002/jmri.26581.
DOI: 10.1002/jmri.26581

Vargas H.A., Wassberg C., Akin O., Hricak H. MR imaging of treated prostate cancer. Radiology 2012;262(1):26–42. DOI: 10.1148/radiol.11101996.
DOI: 10.1148/radiol.11101996

Scialpi M., Martorana E., Scialpi P. et al. MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turkish J Urol 2021;47(6):448–51. DOI: 10.5152/tud.2021.21274.
DOI: 10.5152/tud.2021.21274

Franiel T., Lüdemann L., Taupitz M. MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequen. Radiother Oncol 2009;93(2):241–5. DOI: 10.1016/j.radonc.2009.08.016.
DOI: 10.1016/j.radonc.2009.08.016

Schiavina R., Ceci F., Borghesi M. et al. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharm 2013;6(2):92–5. DOI:10.2174/1874471011306020005.
DOI: 10.2174/1874471011306020005

Sanguineti G., Bertini L., Faiella A. et al. Response on DCE-MRI predicts outcome of salvage radiotherapy for local recurrence after radical prostatectomy. Tumori 2021;107(1):55–63. DOI: 10.1177/0300891620908950.
DOI: 10.1177/0300891620908950

Valle L.F., Greer M.D., Shih J.H. et al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol 2018;24(1):46–53. DOI: 10.5152/dir.2018.17285.
DOI: 10.5152/dir.2018.17285

Tamada T., Sone T., Jo Y. et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 2011;197(2):408–14. DOI: 10.2214/AJR.10.5772.
DOI: 10.2214/AJR.10.5772

Alonzo F., Melodelim C., Bratan F. et al. Detection of locally radiorecurrent prostate cancer at multiparametric MRI: Can dynamic contrast-enhanced imaging be omitted? Diagn Interv Imaging 2016;97(4):433–41. DOI: 10.1016/j.diii.2016.01.008.
DOI: 10.1016/j.diii.2016.01.008

Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;19(3):761–9. DOI: 10.1007/s00330-008-1174-8.
DOI: 10.1007/s00330-008-1174-8

Sandgren K., Westerlinck P., Jonsson J.H. et al. Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomy-A Systematic Review. Eur Urol Focus 2019;5(4):550–60. DOI: 10.1016/j.euf.2017.11.001.
DOI: 10.1016/j.euf.2017.11.001

Barchetti F., Panebianco V. Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy. Biomed Res Int 2014;2014:316272. DOI: 10.1155/2014/316272.
DOI: 10.1155/2014/316272

Kwon T., Kim J.K., Lee C. et al. Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging. Prostate Int 2018;6(1):12–7. DOI: 10.1016/j.prnil.2017.05.002.
DOI: 10.1016/j.prnil.2017.05.002

Kitajima K., Hartman R.P., Froemming A.T. et al. Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI. AJR Am J Roentgenol 2015;205(4):807–16. DOI: 10.2214/AJR.14.14275.
DOI: 10.2214/AJR.14.14275

Panebianco V., Barchetti F., Sciarra A. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013;23(6):1745–52. DOI: 10.1007/s00330-013-2768-3.
DOI: 10.1007/s00330-013-2768-3

Casciani E., Polettini E., Carmenini E. et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008;190(5):1187–92. DOI: 10.2214/AJR.07.3032.
DOI: 10.2214/AJR.07.3032

Litwin M.S., Tan H.J. The Diagnosis and treatment of prostate cancer: a review. JAMA 2017;317(24):2532–42. DOI: 10.1001/jama.2017.7248.
DOI: 10.1001/jama.2017.7248

Nanni C., Schiavina R., Brunocilla E. et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med 2015;40(8):386–91. DOI: 10.1097/RLU.0000000000000849.
DOI: 10.1097/RLU.0000000000000849

Calais J., Fendler W.P., Herrmann K. et al. Comparison of 68GaPSMA-11 and 18F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med 2018;59(5):789–94. DOI: 10.2967/jnumed.117.203257.
DOI: 10.2967/jnumed.117.203257

Evangelista L., Briganti A., Fanti S. et al. New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 2016;70(1):161–75. DOI: 10.1016/j.eururo.2016.01.029.
DOI: 10.1016/j.eururo.2016.01.029

Calais J., Ceci F., Eiber M. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, singlearm, comparative imaging trial. Lancet Oncol 2019;20(9):1286–94. DOI: 10.1016/S1470-2045(19)30415-2.
DOI: 10.1016/S1470-2045(19)30415-2

Afshar-Oromieh A., Vollnberg B., Alberts I. et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging 2019;46(11):2289–97. DOI: 10.1007/s00259-019-04438-w.
DOI: 10.1007/s00259-019-04438-w

Lindenberg L., Mena E., Turkbey B. et al. Evaluating biochemically recurrent prostate cancer: histologic validation of 18F-DCFPyL PET/CT with comparison to multiparametric MRI. Radiology 2020;296(3):564–72. DOI: 10.1148/radiol.2020192018.
DOI: 10.1148/radiol.2020192018

Van den Broeck T., van den Bergh R.C.N., Briers E. et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus 2020;6(2):231–4. DOI: 10.1016/j.euf.2019.06.004.
DOI: 10.1016/j.euf.2019.06.004

Pecoraro M., Turkbey B., Purysko A.S. et al. Diagnostic accuracy and observer agreement of the MRI prostate imaging for recurrence reporting assessment score. Radiology 2022 304(2):342–50. DOI: 10.1148/radiol.212252.
DOI: 10.1148/radiol.212252

Bergaglio C., Giasotto V., Marcenaro M. et al. The Role of mpMRI in the assessment of prostate cancer recurrence using the PI-RR system: diagnostic accuracy and interobserver agreement in readers with different expertise. Diagnostics (Basel) 2023;13(3):387. DOI: 10.3390/diagnostics13030387.
DOI: 10.3390/diagnostics13030387